source
- Eli Lilly leads biotech M&A in H1, leveraging obesity drug success and trillion-dollar scaleEli Lilly, already the largest pharmaceutical company, has emerged as a leading buyer of biotech assets in the first half of 2026. Its trillion-dollar market size and recent successes in obesity t…
- ARPA-H earmarks $160 million for custom gene-editing therapies, sparking debate on adequacyARPA-H announced a $160 million investment to support development of bespoke gene‑editing treatments. This follows a recent case where an infant was rescued from a lethal disease using a personaliz…